|
Mutation Information
|
Mutation Site
|
A181S |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.A181T+rt.A181S;rt.M204I+rt.A181S;rt.L180M+rt.M204I+rt.A181S;rt.L180M+rt.M204I+rt.A181V+rt.A181S;rt.L180M+rt.M204I+rt.A181C+rt.A181S;rt.L180M+rt.M204V+rt.A181S;rt.L180M+rt.M204V+rt.A181C+rt.A181S;rt.L180M+rt.M204V+rt.M204I+rt.A181S;rt.N236T+rt.A181S;rt.N236T+rt.A181T+rt.A181S;rt.N236T+rt.A181V+rt.A181S;rt.A181V+rt.A181S;rt.T184I+rt.M204I+rt.A181S;rt.L180M+rt.T184I+rt.M204I+rt.A181S;rt.T184G+rt.T184I+rt.M204I+rt.A181S;rt.L180M+rt.T184I+rt.M204V+rt.M204I+rt.A181S;rt.L180M+rt.T184A+rt.T184I+rt.T184V+rt.T184I+rt.M204V+rt.M204I+rt.A181S;rt.L180M+rt.T184S+rt.T184I+rt.T184F+rt.T184I+rt.T184A+rt.T184I+rt.T184I+rt.M204V+rt.M204I+rt.A181T+rt.A181S;rt.L180M+rt.S202G+rt.M204V+rt.A181S;rt.L180M+rt.S202G+rt.M204V+rt.M204I+rt.A181S;rt.M250V+rt.T184I+rt.M204I+rt.A181S;rt.L180M+rt.S202G+rt.T184I+rt.M204V+rt.A181S;rt.L180M+rt.S202G+rt.T184I+rt.M204V+rt.M204I+rt.A181V+rt.A181S;rt.L180M+rt.S202G+rt.M204V+rt.M204I+rt.A181V+rt.A181S;rt.N236T+rt.T184M+rt.T184I+rt.M204I+rt.A181T+rt.A181S |
|
Genotype/Subtype
|
B;C;D |
|
Relevant Drug
|
lamivudine (LAM);adefovir dipivoxil (ADV);entecavir (ETV) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
32569703
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2020 |
|
Journal
|
Antiviral research |
|
Title
|
Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. |
|
Author
|
Chen R,Liu Y,Luo D,Si L,Huang B,Wang J,Li X,Cheng F,Xu D,Duan C |
|
Evidence
|
Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients
|
|
|
HBV Mutation Detail Information